> U.K.-based Almac Group has received GMP accreditation from Singapore's Health Sciences Authority, making it the first full-service clinical trial packaging and distribution organization to do so in Singapore. Release
> Australia-listed Starpharma has licensed its Dendrimer Drug Delivery platform to AstraZeneca ($AZN) to investigate early-stage cancer compounds after the two companies have been working together for a number of years, Starpharma said in a release. Release
> Device and pharmaceutical marketing firm ZS has opened a Singapore office for its 5th location in Asia. Release
> India's Dr. Reddy's Institute of Life Sciences will expand collaboration with startups in areas of metabolic disorders, immunology and zebrafish biology to join about 20 companies, including Dr. Reddy's ($RDY), that have conducted projects with the institute since its inception. Report
> Japan's Pharmaceuticals and Medical Devices Agency has updated English-language safety guidelines on a range of pharmaceuticals and medical devices. Website
> Japan's Seikagaku has terminated development of SI-615, an adenosine A3 receptor agonist candidate, and ended a license deal for the compound from Israel's Can-Fite BioPharma obtained in 2006 for development, manufacture, and marketing. Release (PDF)
> U.S.-based International Stem Cell has signed a second phase R&D agreement with Japan's Rohto Pharmaceutical on the use of human parthenogenetic neural stem cells in Rohto's research aimed at possible treatment of degenerative eye disorders. The second phase could lead to commercial development of any candidates, International Stem Cell said. Release
> China Biologic Products said that its Shandong Taibang Biological Products subsidiary has received approval to setup a branch plasma collection unit in Shandong Province in Zaozhuang City.Release